Impact of adjunctive thiazolidinedione therapy on blood lipid levels and glycemic control in patients with type 2 diabetes

References

• Grundy SM, Benjamin IJ, Burke GL et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1999;100:1134–46
   PubMed Web of Science ®Google Scholar
• Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339: 229–34
   Google Scholar
• Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434–44
   PubMed Web of Science ®Google Scholar
• Wingard DL, Barrett-Connor EL, Scheidt-Nave C, McPhillips JB. Prevalence of cardiovascular and renal complications in older adults with normal or impaired glucose tolerance or NIDDM. A population-based study. Diabetes Care 1993;16:1022–5
   PubMed Web of Science ®Google Scholar
• Nowak SN, Jaber LA. Aspirin dose for prevention of cardiovascular disease in diabetics. Ann Pharmacother 2003;37:116–21
   PubMed Web of Science ®Google Scholar
• McFarlane SI, Kumar A, Sowers JR. Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol 2003;91:30H–7H
   Google Scholar
• Fonseca VA. Management of diabetes mellitus and insulin resistance in patients with cardiovascular disease. Am J Cardiol 2003;92:50J–60J
   Google Scholar
• Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383–93
   PubMed Web of Science ®Google Scholar
• McFarlane SI, Jacober SJ, Winer N et al. Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. Diabetes Care 2002;25:718–23
   PubMed Web of Science ®Google Scholar
• George PB, Tobin KJ, Corpus RA, Devlin WH, O’Neill WW. Treatment of cardiac risk factors in diabetic patients: How well do we follow the guidelines? Am Heart J 2001;142:857–63
   Google Scholar
• Grant RW, Cagliero E, Murphy-Sheehy P, Singer DE, Nathan DM, Meigs JB. Comparison of hyperglycemia, hypertension, and hypercholesterolemia management in patients with type 2 diabetes. Am J Med 2002;112: 603–9
   Google Scholar
• Phillips LS, Grunberger G, Miller E, Patwardhan R, Rappaport EB, Salzman A. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care 2001;24:308–15
   PubMed Web of Science ®Google Scholar
• Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 2000;283:1695–702
   PubMed Web of Science ®Google Scholar
• Wolffenbuttel BH, Gomis R, Squatrito S, Jones NP, Patwardhan RN. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients. Diabet Med 2000;17: 40–7
   Google Scholar
• Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther 2000;22:1395–409
   Google Scholar
• Miyazaki Y, Mahankali A, Matsuda M et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 2001;24:710–9
   PubMed Web of Science ®Google Scholar
• Rosenblatt S, Miskin B, Glazer NB, Prince MJ, Robertson KE. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Art Dis 2001;12: 413–23
   Google Scholar
• Kipnes MS, Krosnick A, Rendell MS, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med 2001;111:10–7
   PubMed Web of Science ®Google Scholar
• Mayerson AB, Hundal RS, Dufour S et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 2002;51:797–802
   PubMed Web of Science ®Google Scholar
• Patel J, Anderson RJ, Rappaport EB. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study. Diabetes Obes Metab 1999;1: 165–72
   Google Scholar
• Yamasaki Y, Kawamori R, Wasada T et al. Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM. AD-4833 Glucose Clamp Study Group, Japan. Tohoku J Exp Med 1997;183: 173–83
   Google Scholar
• ACTOS™ (pioglitazone hydrochloride) tablets [package insert]. Lincolnshire, Ill: Takeda Pharmaceuticals America, 2002
   Google Scholar
• Avandia® (rosiglitazone maleate) tablets [package insert]. Philadelphia, Pa: SmithKline Beecham Pharmaceuticals, 2001
   Google Scholar
• King AB. A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones. Diabetes Care 2000;23:557
   PubMed Web of Science ®Google Scholar
• Gegick CG, Altheimer MD. Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice. Endocr Pract 2001;7:162–9
   PubMedGoogle Scholar
• LaCivita KA, Villarreal G. Differences in lipid profiles of patients given rosiglitazone followed by pioglitazone. Curr Med Res Opin 2002;18:363–70
   PubMed Web of Science ®Google Scholar
• Khan MA, St Pete JV, Xue JL. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 2002;25:708–11
   PubMed Web of Science ®Google Scholar
• Zar JH. Biostatistical Analysis, 3rd edn. New Jersey: Prentice Hall, 1996
   Google Scholar
• Boyle PJ, King AB, Olansky L et al. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records. Clin Ther 2002;24:378–96
   PubMed Web of Science ®Google Scholar
• The EVIDENT Study – data on file. Thomson Health Economics Research, Secaucus, New Jersey
   Google Scholar
• Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000;342:1878–86
   PubMed Web of Science ®Google Scholar
• Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000;342:1887–92
   PubMed Web of Science ®Google Scholar
• Shepherd J, Cobbe SM, Ford I et al. and The West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301–7
   Google Scholar
• Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615–22
   Google Scholar
• Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997;20:614–20
   Google Scholar
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383–9
   PubMed Web of Science ®Google Scholar
• Sacks FM, Pfeffer MA, Moye LA et al. and The Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001–9
   Google Scholar
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7–22
   PubMed Web of Science ®Google Scholar
• Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998;339:1349–57
   PubMed Web of Science ®Google Scholar
• Rubins HB, Robins SJ, Collins D et al. and Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999;341:410–8
   Google Scholar
• Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000;102:21–7
   PubMedGoogle Scholar
• Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001;357:905–10
   PubMed Web of Science ®Google Scholar
• Tenkanen L, Manttari M, Manninen V. Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study. Circulation 1995;92:1779–85
   PubMed Web of Science ®Google Scholar
• Parulkar AA, Pendergrass ML, Granda-Ayala R, Lee TR, Fonseca VA. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 2001;134:61–71
   PubMed Web of Science ®Google Scholar
• Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamura Y. Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001;86: 3452–6
   Google Scholar
• Raji A, Seely EW, Bekins SA, Williams GH, Simonson DC. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care 2003;26: 172–8
   PubMed Web of Science ®Google Scholar
• Igarashi M, Hirata A, Yamaguchi H et al. Characterization of an inhibitory effect of pioglitazone on balloon-injured vascular smooth muscle cell growth. Metabolism 2001;50:955–62
   PubMed Web of Science ®Google Scholar
• Sidell R, Cole M, Draper N, Clarke K, Buckingham R. Rosiglitazone prevents ischaemic injury in the obese zucker rat heart. Diabetes 2001;50:A68–A69
   Web of Science ®Google Scholar
• Scherbaum W, Göke B, for the German Pioglitazone Study Group. Pioglitazone reduces blood pressure in patients with type 2 diabetes mellitus. Diabetes 2001;50:A462
   Google Scholar